Mersana Therapeutics, Inc. (MRSN)
Jan 6, 2026 - MRSN was delisted (reason: acquired by DAWN)
29.08
+0.04 (0.14%)
Inactive · Last trade price on Jan 5, 2026
Mersana Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 56.39 | 107.75 | 174.56 | 128.89 | 177.95 | 255.09 |
Short-Term Investments | - | 26.87 | 34.52 | 151.83 | - | - |
Cash & Short-Term Investments | 56.39 | 134.62 | 209.08 | 280.71 | 177.95 | 255.09 |
Cash Growth | -63.66% | -35.61% | -25.52% | 57.75% | -30.24% | 155.63% |
Accounts Receivable | 0.17 | - | - | 30 | - | - |
Other Current Assets | 3.43 | 2.28 | 4.97 | 8.51 | 10.95 | 3.49 |
Total Current Assets | 59.99 | 136.9 | 214.06 | 319.22 | 188.9 | 258.58 |
Net Property, Plant & Equipment | 2.2 | 6.78 | 11.53 | 14.46 | 14.86 | 12.67 |
Other Long-Term Assets | 0.5 | 0.98 | 0.48 | 0.66 | 2.36 | 2.15 |
Total Assets | 62.69 | 144.66 | 226.06 | 334.34 | 206.11 | 273.4 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 2.39 | 4.33 | 7.32 | 13.95 | 12.32 | 8.34 |
Accrued Expenses | 14.81 | 18.96 | 21.9 | 43.18 | 28.72 | 16.15 |
Short-Term Debt | - | 12.5 | 2.08 | - | - | - |
Current Portion of Leases | 2.29 | 3.86 | 3.25 | 2.8 | 2.3 | 1.44 |
Unearned Revenue | 23.77 | 22.17 | 28.15 | 30.61 | 3.94 | 3.99 |
Other Current Liabilities | - | 0.64 | 0.94 | 0.99 | 0.24 | 0.09 |
Total Current Liabilities | 43.27 | 62.46 | 63.64 | 91.53 | 47.52 | 30 |
Long-Term Debt | - | 10.95 | 23.15 | 24.93 | 24.63 | 4.98 |
Long-Term Leases | - | 1.29 | 5.15 | 8.58 | 11.25 | 10.16 |
Other Long-Term Liabilities | 78.95 | 79.47 | 97.22 | 117.25 | 0.97 | 0.17 |
Total Long-Term Liabilities | 78.95 | 91.71 | 125.52 | 150.75 | 36.85 | 15.31 |
Total Liabilities | 122.22 | 154.17 | 189.16 | 242.28 | 84.37 | 45.31 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | - | - | 0 | 0.01 | 0.01 | 0 |
Additional Paid-in Capital | 891.98 | 886.03 | 863.24 | 746.89 | 572.21 | 508.5 |
Accumulated Other Comprehensive Income | - | 0.01 | 0.01 | -0.15 | - | - |
Retained Earnings | -951.52 | -895.55 | -826.36 | -654.69 | -450.48 | -280.42 |
Shareholders' Equity | -59.54 | -9.51 | 36.89 | 92.06 | 121.74 | 228.08 |
Total Liabilities & Equity | 62.69 | 144.66 | 226.06 | 334.34 | 206.11 | 273.4 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 2.29 | 28.6 | 33.63 | 36.3 | 38.18 | 16.57 |
Net Cash (Debt) | 54.1 | 106.02 | 175.45 | 244.41 | 139.77 | 238.52 |
Net Cash Growth | -56.26% | -39.57% | -28.21% | 74.87% | -41.40% | 159.19% |
Net Cash Per Share | 10.87 | 21.63 | 37.78 | 65.24 | 49.51 | 96.98 |
Book Value | -59.54 | -9.51 | 36.89 | 92.06 | 121.74 | 228.08 |
Book Value Per Share | -11.97 | -1.94 | 7.94 | 24.57 | 43.12 | 92.74 |
Tangible Book Value | -59.54 | -9.51 | 36.89 | 92.06 | 121.74 | 228.08 |
Tangible Book Value Per Share | -11.97 | -1.94 | 7.94 | 24.57 | 43.12 | 92.74 |